메뉴 건너뛰기




Volumn 11, Issue 10, 1997, Pages 1551-1560

Management of Progressive Metastatic Prostate Cancer

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTRAMUSTINE; ETIDRONIC ACID; ETOPOSIDE; FLUTAMIDE; GONADORELIN; GONADORELIN DERIVATIVE; HYDROCORTISONE; KETOCONAZOLE; LIAROZOLE; MEGESTROL ACETATE; MITOXANTRONE; NILUTAMIDE; PACLITAXEL; PAMIDRONIC ACID; PHENYLACETIC ACID; PREDNISONE; R 72521; RHENIUM 186; STRONTIUM 89; SURAMIN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

EID: 0030828844     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (20)

References (95)
  • 2
    • 0018765410 scopus 로고
    • Prostatic carcinoma
    • Klein LA: Prostatic carcinoma. N Engl J Med 300:824-833, 1979.
    • (1979) N Engl J Med , vol.300 , pp. 824-833
    • Klein, L.A.1
  • 3
    • 84928580276 scopus 로고
    • Studies on prostatic cancer: 1. the effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
    • Huggins C, Hodges CV: Studies on prostatic cancer: 1. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941
    • (1941) Cancer Res , vol.1 , pp. 293-297
    • Huggins, C.1    Hodges, C.V.2
  • 4
    • 0022345683 scopus 로고
    • Randomized controlled study of orchiectomy vs long acting D-try-6-LHRH microcapsules in advanced proslatic carcinoma
    • Parmer H, Lightman SL, Allen L, et al: Randomized controlled study of orchiectomy vs long acting D-try-6-LHRH microcapsules in advanced proslatic carcinoma. Lancet 2:1201-1205, 1985.
    • (1985) Lancet , vol.2 , pp. 1201-1205
    • Parmer, H.1    Lightman, S.L.2    Allen, L.3
  • 5
    • 0024324367 scopus 로고
    • A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
    • Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989.
    • (1989) N Engl J Med , vol.321 , pp. 419-424
    • Crawford, E.D.1    Eisenberger, M.A.2    McLeod, D.G.3
  • 6
    • 0027457020 scopus 로고
    • Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
    • Janknegt RA, Abbou CC, Bartoletti R, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77-83, 1993.
    • (1993) J Urol , vol.149 , pp. 77-83
    • Janknegt, R.A.1    Abbou, C.C.2    Bartoletti, R.3
  • 7
    • 0028295588 scopus 로고
    • Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer: A meta-analysis of seven randomized double-blinded trials 91056 patients
    • Bertagna C, DeGery A, Hucher M, et al: Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer: A meta-analysis of seven randomized double-blinded trials 91056 patients. Br J Urol 73:396-402, 1994.
    • (1994) Br J Urol , vol.73 , pp. 396-402
    • Bertagna, C.1    DeGery, A.2    Hucher, M.3
  • 8
    • 5944237302 scopus 로고
    • Maximum androgen blockade in advance prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
    • Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advance prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346265-269, 1995.
    • (1995) Lancet , vol.34 , pp. 6265-6269
  • 9
    • 5944226796 scopus 로고    scopus 로고
    • Meta analysis of published randomized clinical trials for MAB in prostate cancer
    • Caubet J-F, Tosteson TD, Dong W, et al: Meta analysis of published randomized clinical trials for MAB in prostate cancer (abstract 654) Proc Am Soc Clin Oncol 15-254, 1996.
    • (1996) Proc am Soc Clin Oncol , vol.15 , pp. 254
    • Caubet, J.-F.1    Tosteson, T.D.2    Dong, W.3
  • 10
    • 0019382176 scopus 로고
    • Bilateral orchiectomy for carcinoma of prostate: Response of serum testosterone and clinical response to estrogen therapy
    • Klugo RC, Farah RN, Cerny JC: Bilateral orchiectomy for carcinoma of prostate: Response of serum testosterone and clinical response to estrogen therapy. Urology 17:49-50, 1981.
    • (1981) Urology , vol.17 , pp. 49-50
    • Klugo, R.C.1    Farah, R.N.2    Cerny, J.C.3
  • 11
    • 0000597499 scopus 로고
    • Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases
    • Nesbit RM, Baum WC: Endocrine control of prostatic carcinoma. Clinical and statistical survey of 1818 cases. JAMA 143:1317-1320, 1950.
    • (1950) JAMA , vol.143 , pp. 1317-1320
    • Nesbit, R.M.1    Baum, W.C.2
  • 12
    • 85004947039 scopus 로고
    • Orchiectomy after presumed estrogen failure in the treatment of carcinoma of the prostate
    • Bjorn CL, Gray CP, Strauss E: Orchiectomy after presumed estrogen failure in the treatment of carcinoma of the prostate. West J Med 130:363-364, 1979.
    • (1979) West J Med , vol.130 , pp. 363-364
    • Bjorn, C.L.1    Gray, C.P.2    Strauss, E.3
  • 13
    • 0019478982 scopus 로고
    • The response of metastatic adenocareinoma of the prostate 10 exogenous testosterone
    • Fowler JE, Whitmore WF: The response of metastatic adenocareinoma of the prostate 10 exogenous testosterone. J Urol 126:372-375, 1981.
    • (1981) J Urol , vol.126 , pp. 372-375
    • Fowler, J.E.1    Whitmore, W.F.2
  • 14
    • 0026021196 scopus 로고
    • Response to orchiectomy following zoladex therapy for metastatic prostate carcinoma
    • Silver RI, Straus FH, Vogelzang NJ, et al: Response to orchiectomy following zoladex therapy for metastatic prostate carcinoma. Urology 37:17-21, 1991.
    • (1991) Urology , vol.37 , pp. 17-21
    • Silver, R.I.1    Straus, F.H.2    Vogelzang, N.J.3
  • 15
    • 0027944451 scopus 로고
    • Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer. A Southwest Oncology Group Report
    • Hussain M, Wolf M, Marshall E, et al: Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer. A Southwest Oncology Group Report. J Clin Oncol 12:1868-1875, 1994.
    • (1994) J Clin Oncol , vol.12 , pp. 1868-1875
    • Hussain, M.1    Wolf, M.2    Marshall, E.3
  • 16
    • 0027487289 scopus 로고
    • Importance of continued testicular suppression in hormone refractory prostate cancer
    • Taylor CD, Elson P, Trump DL: Importance of continued testicular suppression in hormone refractory prostate cancer. J Clin Oncol 11:2167-2172, 1993.
    • (1993) J Clin Oncol , vol.11 , pp. 2167-2172
    • Taylor, C.D.1    Elson, P.2    Trump, D.L.3
  • 17
    • 0029011116 scopus 로고
    • Mutation of the androgen receptor gene in meta static androgen-independent prostate cancer
    • Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen receptor gene in meta static androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995.
    • (1995) N Engl J Med , vol.332 , pp. 1393-1398
    • Taplin, M.E.1    Bubley, G.J.2    Shuster, T.D.3
  • 18
    • 0028838151 scopus 로고
    • The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP
    • Figg WD, McCall NA, Reed E, et al: The in vitro response of four antisteroid receptor agents on the hormone responsive prostate cancer cell line LNCaP. Oncology Reports 2:295-298, 1995.
    • (1995) Oncology Reports , vol.2 , pp. 295-298
    • Figg, W.D.1    McCall, N.A.2    Reed, E.3
  • 19
    • 0024351830 scopus 로고
    • Aberrant response in vitro of hormone-responsive prostate cancer cells to anti-androgens
    • Wilding G, Chen M, Gelman EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to anti-androgens. Prostate 14:103-115, 1989.
    • (1989) Prostate , vol.14 , pp. 103-115
    • Wilding, G.1    Chen, M.2    Gelman, E.P.3
  • 20
    • 0029084601 scopus 로고
    • The anti-androgen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients
    • Small EJ, Srinivas S: The anti-androgen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 76:1428-1434, 1995.
    • (1995) Cancer , vol.76 , pp. 1428-1434
    • Small, E.J.1    Srinivas, S.2
  • 21
    • 0027203411 scopus 로고
    • Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
    • Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993.
    • (1993) J Clin Oncol , vol.11 , pp. 1566-1572
    • Scher, H.I.1    Kelly, W.K.2
  • 22
    • 0028907804 scopus 로고
    • Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
    • Figg WD, Sartor O, Cooper MR, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414, 1995.
    • (1995) Am J Med , vol.98 , pp. 412-414
    • Figg, W.D.1    Sartor, O.2    Cooper, M.R.3
  • 23
    • 0028256111 scopus 로고
    • Prostate specific antigen decline after Casodex withdrawal: Evidence for an anti-androgen withdrawal syndrome
    • Small FJ, Carroll PR: Prostate specific antigen decline after Casodex withdrawal: Evidence for an anti-androgen withdrawal syndrome. Urology 43:408-410, 1994.
    • (1994) Urology , vol.43 , pp. 408-410
    • Small, F.J.1    Carroll, P.R.2
  • 24
    • 0343246680 scopus 로고    scopus 로고
    • A double-blind assessment of anti-androgen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer
    • Small EJ, Schellhammer P, Venner P, et al: A double-blind assessment of anti-androgen withdrawal from Casodex or Eulexin therapy while continuing luteinizing hormone releasing hormone analogue therapy for patients with stage D2 prostate cancer (abstract 658). Proc Am Soc Clin Oncol 15:255, 1996
    • (1996) Proc am Soc Clin Oncol , vol.15 , pp. 255
    • Small, E.J.1    Schellhammer, P.2    Venner, P.3
  • 25
    • 0029007052 scopus 로고
    • Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the anti-androgen withdrawal syndrome
    • Dawson NA, McLeod DG: Dramatic prostate specific antigen decline in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the anti-androgen withdrawal syndrome J Urol 153:1946-1947, 1995.
    • (1995) J Urol , vol.153 , pp. 1946-1947
    • Dawson, N.A.1    McLeod, D.G.2
  • 26
    • 5944251127 scopus 로고    scopus 로고
    • PSA response to megace withdrawal in hormone refractory prostate cancer (HRPC)
    • Wehbe TW, Wehbe P, Akerly III W, et al: PSA response to megace withdrawal in hormone refractory prostate cancer (HRPC) (abstract 667). Proc Am Soc Clin Oncol 15:257, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 257
    • Wehbe, T.W.1    Wehbe, P.2    Akerly III, W.3
  • 27
    • 0029619536 scopus 로고    scopus 로고
    • Hormone and antihormone withdrawal' Implications for the management of androgen-independent prostate cancer
    • Scher HI, Zhang ZF, Nanus D, et al: Hormone and antihormone withdrawal' Implications for the management of androgen-independent prostate cancer. Urology 47(suppl 1A):61-69, 1996.
    • (1996) Urology , vol.47 , Issue.SUPPL. 1A , pp. 61-69
    • Scher, H.I.1    Zhang, Z.F.2    Nanus, D.3
  • 28
    • 0027249588 scopus 로고
    • Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy
    • Dupont A, Gomez JL, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993.
    • (1993) J Urol , vol.150 , pp. 908-913
    • Dupont, A.1    Gomez, J.L.2    Cusan, L.3
  • 29
    • 0028089068 scopus 로고
    • Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in "hormonerefractory" prostate cancer
    • Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in "hormonerefractory" prostate cancer. J Natl Cancer Inst 86:222-227, 1994.
    • (1994) J Natl Cancer Inst , vol.86 , pp. 222-227
    • Sartor, O.1    Cooper, M.2    Weinberger, M.3
  • 30
    • 0029982140 scopus 로고    scopus 로고
    • Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone-refractory prostate cancer
    • Figg WD, Dawson NA, Middleman MN et al. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone-refractory prostate cancer. Acta Oncol 35:763-765, 1996.
    • (1996) Acta Oncol , vol.35 , pp. 763-765
    • Figg, W.D.1    Dawson, N.A.2    Middleman, M.N.3
  • 31
    • 0038417687 scopus 로고
    • High dose casodex for prostate cancer: PSA decline in patients with flutamide withdrawal responses
    • Liebertz C, Kelly WK, Theodoulou M et al: High dose casodex for prostate cancer: PSA decline in patients with flutamide withdrawal responses (abstract 603). Proc Am Soc Clin Oncol 14:232, 1995
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 232
    • Liebertz, C.1    Kelly, W.K.2    Theodoulou, M.3
  • 32
    • 0343682326 scopus 로고    scopus 로고
    • Bicalutamide for androgen-independent prostate cancer
    • Fenton MA, Rode P, Constatine M et al: Bicalutamide for androgen-independent prostate cancer (abstract 684) Proc Am Soc Clin Oncol 15:262, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 262
    • Fenton, M.A.1    Rode, P.2    Constatine, M.3
  • 33
    • 0002575776 scopus 로고    scopus 로고
    • Phase II mal of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A SWOG Study (SWOG 9235)
    • Kucuk O, Blumenstein, Moinponr C, et al: Phase II mal of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A SWOG Study (SWOG 9235) (abstract 618) Proc Am Soc Clin Oncol 15:245, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 245
    • Kucuk, O.1    Blumenstein2    Moinponr, C.3
  • 34
    • 0001170653 scopus 로고    scopus 로고
    • Megestrol acetate in men with hormone-refractory prostate cancer: Prostate specific antigen response and anti-androgen withdrawal: CALGB 9181
    • Dawson NA, Small EJ, Conaway M, et al: Megestrol acetate in men with hormone-refractory prostate cancer: Prostate specific antigen response and anti-androgen withdrawal: CALGB 9181 (abstract 601). Proc Am Soc Clin Oncol 15:241, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 241
    • Dawson, N.A.1    Small, E.J.2    Conaway, M.3
  • 35
    • 0343846842 scopus 로고
    • Significant activity by high dose tamoxifen in hormone refractory prostate cancer
    • Bergan RC, Blagosklonny M, Dawson NA, et al: Significant activity by high dose tamoxifen in hormone refractory prostate cancer (abstract 637). Proc Am Soc Clin Oncol 14:241, 1995.
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 241
    • Bergan, R.C.1    Blagosklonny, M.2    Dawson, N.A.3
  • 36
    • 0024389842 scopus 로고
    • High-dose ketoconazole in advance hormone-refractory prostate cancer. Endocrinologic and clinical effects
    • Trump DL, Havlin KH, Messing EM, et al High-dose ketoconazole in advance hormone-refractory prostate cancer. Endocrinologic and clinical effects. J Clin Oncol 7:1093-1098, 1989.
    • (1989) J Clin Oncol , vol.7 , pp. 1093-1098
    • Trump, D.L.1    Havlin, K.H.2    Messing, E.M.3
  • 37
    • 0030999075 scopus 로고    scopus 로고
    • Keto conazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
    • Small EJ, Egan B, Apodaca D, et al: Keto conazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 4(5): 1204-1207, 1997.
    • (1997) J Urol , vol.4 , Issue.5 , pp. 1204-1207
    • Small, E.J.1    Egan, B.2    Apodaca, D.3
  • 38
    • 0000855450 scopus 로고
    • Cortisone treatment in advance carcinoma of the prostate
    • Miller CM, Hinman F: Cortisone treatment in advance carcinoma of the prostate. J Urol 72:485-496, 1954.
    • (1954) J Urol , vol.72 , pp. 485-496
    • Miller, C.M.1    Hinman, F.2
  • 39
    • 0024535895 scopus 로고
    • Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response
    • Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
    • (1989) J Clin Oncol , vol.7 , pp. 590-597
    • Tannock, I.1    Gospodarowicz, M.2    Meakin, W.3
  • 40
    • 0026625134 scopus 로고
    • Suramin and prostate cancer: The role of hydrocortisone
    • Harland SJ, Duchesne GM: Suramin and prostate cancer: The role of hydrocortisone (letter) Eur J Cancer 28A:1295, 1992.
    • (1992) Eur J Cancer , vol.28 A , pp. 1295
    • Harland, S.J.1    Duchesne, G.M.2
  • 41
    • 85004984992 scopus 로고
    • Prostate specific antigen levels and clinical response to low-dose dexamethasone for hormone refractory metastatic prostate cancer
    • Storlie JA, Buckner JC, Wiseman GA, et al: Prostate specific antigen levels and clinical response to low-dose dexamethasone for hormone refractory metastatic prostate cancer (abstract 726). Proc Am Soc Clin Oncol 13:235, 1994.
    • (1994) Proc Am Soc Clin Oncol , vol.13 , pp. 235
    • Storlie, J.A.1    Buckner, J.C.2    Wiseman, G.A.3
  • 42
    • 0024464395 scopus 로고
    • Estramustine-A nitrogen mustard/steroid with antimicrotubule activity
    • Tew KD, Stearns, ME: Estramustine-A nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther 43:299-319, 1989.
    • (1989) Pharmacol Ther , vol.43 , pp. 299-319
    • Tew, K.D.1    Stearns, M.E.2
  • 43
    • 84966070158 scopus 로고
    • Role of estramustine phosphate in the treatment of prostate cancer
    • Schaefers H (ed). Utrecht
    • Benson RC: Role of estramustine phosphate in the treatment of prostate cancer, in Schaefers H (ed). Estracyst, Scientific Edition 2, pp 35-64. Utrecht, 1988.
    • (1988) Estracyst, Scientific Edition 2 , pp. 35-64
    • Benson, R.C.1
  • 44
    • 0027486654 scopus 로고
    • Taxol in advanced, hormone-refractory carcinoma of the prostate
    • Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate. Cancer 72:2457-2460, 1993.
    • (1993) Cancer , vol.72 , pp. 2457-2460
    • Roth, B.J.1    Yeap, B.Y.2    Wilding, G.3
  • 45
    • 0028226103 scopus 로고
    • Oral etoposide in the treatment of hormone refractory prostate cancer
    • Hussain M, Pienta KJ, Redman BG, et al: Oral etoposide in the treatment of hormone refractory prostate cancer Cancer 74:100-103, 1994.
    • (1994) Cancer , vol.74 , pp. 100-103
    • Hussain, M.1    Pienta, K.J.2    Redman, B.G.3
  • 46
    • 0027154852 scopus 로고
    • Inhibition of prostate cancer growth by estranmstine and etoposide: Evidence for interactions at the nuclear matrix
    • Pienta KJ, Lehr JE: Inhibition of prostate cancer growth by estranmstine and etoposide: Evidence for interactions at the nuclear matrix. J Urol 149:1622-1625, 1993.
    • (1993) J Urol , vol.149 , pp. 1622-1625
    • Pienta, K.J.1    Lehr, J.E.2
  • 47
    • 0023952134 scopus 로고
    • Anti invasive activity of estramustine on malignant MO4 cells and DU-145 human prostate carcinoma cells in vitro
    • Mareel MM, Storme GA, Dragonett CH, et al: Anti invasive activity of estramustine on malignant MO4 cells and DU-145 human prostate carcinoma cells in vitro. Cancer Res 48:1842-1849, 1988.
    • (1988) Cancer Res , vol.48 , pp. 1842-1849
    • Mareel, M.M.1    Storme, G.A.2    Dragonett, C.H.3
  • 48
    • 0026808448 scopus 로고
    • Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
    • Speicher LA, Barone L, Tew KD: Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 52:4433-4440, 1992.
    • (1992) Cancer Res , vol.52 , pp. 4433-4440
    • Speicher, L.A.1    Barone, L.2    Tew, K.D.3
  • 49
    • 0028104733 scopus 로고
    • Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate
    • Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
    • (1994) J Clin Oncol , vol.12 , pp. 2005-2012
    • Pienta, K.J.1    Redman, B.2    Hussain, M.3
  • 50
    • 1542532447 scopus 로고
    • Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone-refractory disease (HRPC)
    • Hudes G, Nathan F, Chapman A, et al: Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone-refractory disease (HRPC) (abstract 622). Proc Am Soc Clin Oncol 14:237, 1995.
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 237
    • Hudes, G.1    Nathan, F.2    Chapman, A.3
  • 51
    • 0027097763 scopus 로고
    • Phase II study of estramustine and vmblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
    • Hudes GR, Greenberg R, Krigel RL, et al: Phase II study of estramustine and vmblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992.
    • (1992) J Clin Oncol , vol.10 , pp. 1754-1761
    • Hudes, G.R.1    Greenberg, R.2    Krigel, R.L.3
  • 52
    • 0007875652 scopus 로고    scopus 로고
    • A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer
    • Reese D, Burris H, Bellegrun A, et al: A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (abstract 673). Proc Am Soc Clin Oncol 15:259, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 259
    • Reese, D.1    Burris, H.2    Bellegrun, A.3
  • 53
    • 0003965169 scopus 로고    scopus 로고
    • Report of an extended phase II trial of oral estramustine and oral etoposide in the treatment of hormone refractory prostate cancer patients
    • Pienta KJ, Flaherty E, Hussain M, et al: Report of an extended phase II trial of oral estramustine and oral etoposide in the treatment of hormone refractory prostate cancer patients (abstract 681). Proc Am Soc Oncol 15:261, 1996.
    • (1996) Proc Am Soc Oncol , vol.15 , pp. 261
    • Pienta, K.J.1    Flaherty, E.2    Hussain, M.3
  • 54
    • 5944238998 scopus 로고    scopus 로고
    • Preliminary results of estramustine and vinblastine as primary treatment for metastatic prostatic cancer
    • Trudeau M, Aronson S, Bazinet M: Preliminary results of estramustine and vinblastine as primary treatment for metastatic prostatic cancer (abstract 662). Proc Am Soc Clin Oncol 15:256, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 256
    • Trudeau, M.1    Aronson, S.2    Bazinet, M.3
  • 55
    • 5944251250 scopus 로고    scopus 로고
    • Strontium-89, estramustine, and vinblastine in hormone refractory prostate carcinoma: Concurrent chemoradiotherapy
    • Wehbe T, Akerley W, Sloan L, et al. Strontium-89, estramustine, and vinblastine in hormone refractory prostate carcinoma: Concurrent chemoradiotherapy (abstract 682). Proc Am Soc Clin Oncol 15:261, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 261
    • Wehbe, T.1    Akerley, W.2    Sloan, L.3
  • 56
    • 0027511899 scopus 로고
    • Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory proslate cancer
    • Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory proslate cancer. J Clin Oncol 11:607-615, 1993.
    • (1993) J Clin Oncol , vol.11 , pp. 607-615
    • Kelly, W.K.1    Scher, H.I.2    Mazumdar, M.3
  • 57
    • 0027504768 scopus 로고
    • Oral cyclophosphamide for the management of hormone-refractory prostate cancer
    • Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer Br J Urol 72:625-628, 1993
    • (1993) Br J Urol , vol.72 , pp. 625-628
    • Raghavan, D.1    Cox, K.2    Pearson, B.S.3
  • 58
    • 0029923406 scopus 로고    scopus 로고
    • Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
    • Small EJ, Srinivas S, Egan B, et al Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer. J Clin Oncol 14:1617-1625, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 1617-1625
    • Small, E.J.1    Srinivas, S.2    Egan, B.3
  • 59
    • 0024535895 scopus 로고
    • Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response
    • Tannock T, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation if pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989.
    • (1989) J Clin Oncol , vol.7 , pp. 590-597
    • Tannock, T.1    Gospodarowicz, M.2    Meakin, W.3
  • 60
    • 0028208515 scopus 로고
    • Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
    • Moore MJ, Osoba D, Murphy K, et al: Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 12:689-694, 1994
    • (1994) J Clin Oncol , vol.12 , pp. 689-694
    • Moore, M.J.1    Osoba, D.2    Murphy, K.3
  • 61
    • 8944220720 scopus 로고    scopus 로고
    • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate, cancer: A Canadian randomized trial with palliative endpoints
    • Tannock IF, Osoba D, Stockler MR, et al Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate, cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 14:1756-1764, 1996.
    • (1996) J Clin Oncol , vol.14 , pp. 1756-1764
    • Tannock, I.F.1    Osoba, D.2    Stockler, M.R.3
  • 62
    • 0343363359 scopus 로고    scopus 로고
    • Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B (9182) comparing chemotherapy to best supportive care
    • Kantoff PW, Conaway M, Winer E, et al: Hydrocortisone with and without mitoxantrone in patients with hormone-refractory prostate cancer: Preliminary results from a prospective randomized Cancer and Leukemia Group B (9182) comparing chemotherapy to best supportive care (abstract 2013). Proc Am Soc Clin Oncol 14:1748, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.14 , pp. 1748
    • Kantoff, P.W.1    Conaway, M.2    Winer, E.3
  • 63
    • 0027270333 scopus 로고
    • The treatment of painful osseous metastases with phosphorus-32-labeled phosphates
    • Silberstein EB: The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 20, No.3 2(suppl):10-21, 1993.
    • (1993) Semin Oncol , vol.20 , Issue.32 SUPPL. , pp. 10-21
    • Silberstein, E.B.1
  • 64
    • 0028598194 scopus 로고
    • The use of strontium-89 for palliation of pain form bone metastases associated with hormone-refractory prostate cancer
    • Crawford ED, Kozlowski JM, Debruyne FMI, et al: The use of strontium-89 for palliation of pain form bone metastases associated with hormone-refractory prostate cancer. Urology 44:481-485, 1994.
    • (1994) Urology , vol.44 , pp. 481-485
    • Crawford, E.D.1    Kozlowski, J.M.2    Debruyne, F.M.I.3
  • 65
    • 0027252452 scopus 로고
    • Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
    • Porter AT, McEwan AJB, Powe JE, et al Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805-813, 1993.
    • (1993) Int J Radiat Oncol Biol Phys , vol.25 , pp. 805-813
    • Porter, A.T.1    McEwan, A.J.B.2    Powe, J.E.3
  • 66
    • 0028233520 scopus 로고
    • A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
    • Quilty PM, Kirk D, Bolger JJ, et al: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33-40, 1994.
    • (1994) Radiother Oncol , vol.31 , pp. 33-40
    • Quilty, P.M.1    Kirk, D.2    Bolger, J.J.3
  • 67
    • 0026750068 scopus 로고
    • Samarium-153-EDTMP: Pharmacokinetic toxicity and pain response using an escalating dose schedule in treatment of metastalic bone cancer
    • Farhanght M, Holmes RA, Volkert WA, et al: Samarium-153-EDTMP: Pharmacokinetic toxicity and pain response using an escalating dose schedule in treatment of metastalic bone cancer J Nucl Med 33:1451-1458, 1992.
    • (1992) J Nucl Med , vol.33 , pp. 1451-1458
    • Farhanght, M.1    Holmes, R.A.2    Volkert, W.A.3
  • 68
    • 0027521907 scopus 로고
    • Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial
    • Collins C, Eary JF, Donaldson G, et al: Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med 34:1839-1844, 1993.
    • (1993) J Nucl Med , vol.34 , pp. 1839-1844
    • Collins, C.1    Eary, J.F.2    Donaldson, G.3
  • 69
    • 0027958545 scopus 로고
    • Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases
    • Bayouth JE, Macey DJ, Kasi LP, et al: Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35:63-69, 1994.
    • (1994) J Nucl Med , vol.35 , pp. 63-69
    • Bayouth, J.E.1    Macey, D.J.2    Kasi, L.P.3
  • 70
    • 5944244811 scopus 로고    scopus 로고
    • Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma
    • Quick D, Reid R, Hoskin P, et al: Efficacy and safety of 153Sm-EDTMP in alleviating the pain of bone metastases in patients with prostate carcinoma (abstract 1654). Proc Am Soc Clin Oncol 15.514, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 514
    • Quick, D.1    Reid, R.2    Hoskin, P.3
  • 71
    • 0026444214 scopus 로고
    • Rhenium-186 hydroxyethylidene Diphosphonate for the treatment of painful osseous metastases
    • Maxon HR, Thomas, SR, Hertzberg VS, et al: Rhenium-186 hydroxyethylidene Diphosphonate for the treatment of painful osseous metastases. Seinin Nucl Med 23:33-40, 1992
    • (1992) Seinin Nucl Med , vol.23 , pp. 33-40
    • Maxon, H.R.1    Thomas, S.R.2    Hertzberg, V.S.3
  • 72
    • 5944232832 scopus 로고
    • Radiopharmaceutical therapy of cancer pain from bone metastases
    • Somerset, New Jersey, Wiley-Liss
    • Silberstein EB: Radiopharmaceutical therapy of cancer pain from bone metastases, in Prostate Cancer pp 261-268. Somerset, New Jersey, Wiley-Liss, 1994.
    • (1994) Prostate Cancer , pp. 261-268
    • Silberstein, E.B.1
  • 73
    • 0022393635 scopus 로고
    • Generalized increase in bone resorption in carcinomaof the prostate
    • Urwin GH, Percival RC, Harris S, et al: Generalized increase in bone resorption in carcinomaof the prostate. Br J Urol 57:721-723, 1985.
    • (1985) Br J Urol , vol.57 , pp. 721-723
    • Urwin, G.H.1    Percival, R.C.2    Harris, S.3
  • 74
    • 5944227885 scopus 로고
    • Effects of disodium pamidronate in metastatic prostate cancer
    • Clarke NW, McClure J, George NJR: Effects of disodium pamidronate in metastatic prostate cancer (abstract). Eur J Cancer 27(suppl 2):117, 1991.
    • (1991) Eur J Cancer , vol.27 , Issue.2 SUPPL. , pp. 117
    • Clarke, N.W.1    McClure, J.2    George, N.J.R.3
  • 75
    • 0017831729 scopus 로고
    • Suramin: With special reference to onchocerciasis
    • Hawkins F: Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother 15-289-322, 1978.
    • (1978) Adv Pharmacol Chemother , vol.15 , pp. 289-322
    • Hawkins, F.1
  • 76
    • 0024593227 scopus 로고
    • Suramin: An anticancer drug with a unique mechanism of action
    • Stem CA, La Rocca RV, Thomas R, et al: Suramin: An anticancer drug with a unique mechanism of action. J Clin Oncol 7:499-508, 1989.
    • (1989) J Clin Oncol , vol.7 , pp. 499-508
    • Stem, C.A.1    La Rocca, R.V.2    Thomas, R.3
  • 77
    • 0026740863 scopus 로고
    • Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
    • Myers C, Cooper M, Stein CA, et al: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer J Clin Oncol 10:881-889, 1992.
    • (1992) J Clin Oncol , vol.10 , pp. 881-889
    • Myers, C.1    Cooper, M.2    Stein, C.A.3
  • 78
    • 0029127207 scopus 로고
    • Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer
    • Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13:2174-2186, 1995.
    • (1995) J Clin Oncol , vol.13 , pp. 2174-2186
    • Eisenberger, M.A.1    Sinibaldi, V.J.2    Reyno, L.M.3
  • 79
    • 0029078689 scopus 로고
    • Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
    • Dawson NA, Cooper MR, Figg WD, et al: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76:453-462, 1995.
    • (1995) Cancer , vol.76 , pp. 453-462
    • Dawson, N.A.1    Cooper, M.R.2    Figg, W.D.3
  • 80
    • 0029101785 scopus 로고
    • Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
    • Kelly WK, Curley T, Leibertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995.
    • (1995) J Clin Oncol , vol.13 , pp. 2208-2213
    • Kelly, W.K.1    Curley, T.2    Leibertz, C.3
  • 81
    • 0029120380 scopus 로고
    • Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin
    • Bitton RJ, Figg WD, Venzon DJ, et al: Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13:2223-2229, 1995.
    • (1995) J Clin Oncol , vol.13 , pp. 2223-2229
    • Bitton, R.J.1    Figg, W.D.2    Venzon, D.J.3
  • 83
    • 0029120379 scopus 로고    scopus 로고
    • Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer
    • Kobayashi K, Vokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1996
    • (1996) J Clin Oncol , vol.13 , pp. 2196-2207
    • Kobayashi, K.1    Vokes, E.E.2    Vogelzang, N.J.3
  • 84
    • 0029827498 scopus 로고    scopus 로고
    • A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response
    • Bowden CJ, Figg WD, Dawson NA, et al: A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response. Cancer Chemother Pharmacol (39)1-2:1-8, 1996.
    • (1996) Cancer Chemother Pharmacol , vol.1-2 , Issue.39 , pp. 1-8
    • Bowden, C.J.1    Figg, W.D.2    Dawson, N.A.3
  • 86
    • 0027180685 scopus 로고
    • Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate
    • Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate. J Clin Invest 91(5):22W-2295, 1993.
    • (1993) J Clin Invest , vol.91 , Issue.5
    • Samid, D.1    Shack, S.2    Myers, C.E.3
  • 87
    • 5944227884 scopus 로고
    • Phenylacetate induces the production of prostate specific antigen in prostate cancer cells: In vitro and in vivo studies
    • Walls RG, Thibault A, Wood C, et al: Phenylacetate induces the production of prostate specific antigen in prostate cancer cells: In vitro and in vivo studies (abstract 46). Proc Am Soc Clin Oncol 14:86, 1995.
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 86
    • Walls, R.G.1    Thibault, A.2    Wood, C.3
  • 88
    • 0142124545 scopus 로고    scopus 로고
    • Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate
    • Bowling MK, Nelson JB, Tong KP, et al: Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (abstract 43). Proc Am Soc Clin Oncol 15:94, 1996
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 94
    • Bowling, M.K.1    Nelson, J.B.2    Tong, K.P.3
  • 89
    • 0029396721 scopus 로고
    • Phase I/II dose-escalation study of liazorole in patients with stage D. hormone-refractory carcinoma of the prostate
    • Seidmon EJ, Trump DL, Kreis, W, et al: Phase I/II dose-escalation study of liazorole in patients with stage D. hormone-refractory carcinoma of the prostate Ann Surg Oncol 2(6) 550-556, 1995
    • (1995) Ann Surg Oncol , vol.2 , Issue.6 , pp. 550-556
    • Seidmon, E.J.1    Trump, D.L.2    Kreis, W.3
  • 90
    • 5944257998 scopus 로고    scopus 로고
    • Effects of liazorole on PSA levels in patients with relapsed stage D prostate cancer
    • Smith J, Andriole G, Ahmann F, et al: Effects of liazorole on PSA levels in patients with relapsed stage D prostate cancer (abstract 636). Proc Am Soc Clin Oncol 15:250, 1996.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 250
    • Smith, J.1    Andriole, G.2    Ahmann, F.3
  • 91
    • 0025006735 scopus 로고
    • Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer
    • Smith PH, Bono A, da Silva C, et al: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 66.1009-1016, 1990.
    • (1990) Cancer , vol.66 , pp. 1009-1016
    • Smith, P.H.1    Bono, A.2    Da Silva, C.3
  • 92
    • 0021358371 scopus 로고
    • The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer
    • Pollen JJ, Witztum KF, Ashburn WL: The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer. Am J Roentgenol 142:773-776, 1984.
    • (1984) Am J Roentgenol , vol.142 , pp. 773-776
    • Pollen, J.J.1    Witztum, K.F.2    Ashburn, W.L.3
  • 93
    • 5944255278 scopus 로고    scopus 로고
    • Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer
    • in press
    • Smith DC, Dunn RL, Strawderman MS, et al: Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. J Clin Oncol, 1997 (in press).
    • (1997) J Clin Oncol
    • Smith, D.C.1    Dunn, R.L.2    Strawderman, M.S.3
  • 94
    • 5944235085 scopus 로고    scopus 로고
    • Eligibility and response criteria in hormone refractory prostate cancer (PMPC): A need for consensus
    • Dawson NA, Eligibility and response criteria in hormone refractory prostate cancer (PMPC): A need for consensus (abstract 1129). Proc Am Soc Clin Oncol 16:317A, 1997.
    • (1997) Proc Am Soc Clin Oncol , vol.16
    • Dawson, N.A.1
  • 95
    • 0343825245 scopus 로고
    • Post-therapy changes in biochemical markers in patients with androgen independent prostate cancer
    • Kelly WK, Steineck G, Mazumdar M, et al: Post-therapy changes in biochemical markers in patients with androgen independent prostate cancer (abstract 606). Proc Am Soc Clin Oncol 14:233, 1995.
    • (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 233
    • Kelly, W.K.1    Steineck, G.2    Mazumdar, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.